Specifically, the research seeks to develop a targeted alpha particle therapy for treating metastatic prostate cancer (PCa) using a novel dimeric aptamer.  This aptamer efficiently internalizes selectively into PSMA-expressing cells, and allows for the attachment of multiple ²²⁵Ac-chelate complexes to yield a radiopharmaceutical with specific activity greater than that observed with other targeted, systemic radiotherapies.